Dermira (DERM) PT Lowered to $19.00

Dermira (NASDAQ:DERM) had its target price reduced by Needham & Company LLC from $43.00 to $19.00 in a report released on Tuesday morning, The Fly reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on DERM. Zacks Investment Research downgraded shares of Dermira from a hold rating to a sell rating in a research report on Thursday, November 9th. Mizuho reaffirmed a buy rating on shares of Dermira in a research report on Friday, February 23rd. Cowen set a $25.00 price objective on shares of Dermira and gave the stock a buy rating in a research report on Monday, March 5th. Cantor Fitzgerald set a $20.00 price objective on shares of Dermira and gave the stock a buy rating in a research report on Monday, March 5th. Finally, Leerink Swann reaffirmed an outperform rating and issued a $41.00 price objective (down previously from $47.00) on shares of Dermira in a research report on Tuesday, November 7th. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $32.71.

How to Become a New Pot Stock Millionaire

Dermira (NASDAQ:DERM) opened at $9.43 on Tuesday. The company has a debt-to-equity ratio of 1.87, a quick ratio of 5.28 and a current ratio of 5.28. Dermira has a 12-month low of $8.55 and a 12-month high of $36.51.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.09). Dermira had a negative return on equity of 62.07% and a negative net margin of 6,678.29%. The firm had revenue of $1.34 million during the quarter, compared to analysts’ expectations of $1.10 million. sell-side analysts forecast that Dermira will post -4.66 EPS for the current year.

In other Dermira news, CEO Thomas G. Wiggans sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $27.51, for a total transaction of $137,550.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $28.55, for a total transaction of $85,650.00. Following the sale, the insider now directly owns 5,802 shares in the company, valued at approximately $165,647.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,758 shares of company stock worth $948,029. 13.30% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its position in Dermira by 4.0% during the 3rd quarter. Wells Fargo & Company MN now owns 52,995 shares of the biopharmaceutical company’s stock worth $1,431,000 after purchasing an additional 2,025 shares during the last quarter. New York State Common Retirement Fund grew its position in Dermira by 4.8% during the 3rd quarter. New York State Common Retirement Fund now owns 49,993 shares of the biopharmaceutical company’s stock worth $1,350,000 after purchasing an additional 2,308 shares during the last quarter. Quantbot Technologies LP grew its position in Dermira by 75.4% during the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 2,309 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Dermira by 47.7% in the 3rd quarter. SG Americas Securities LLC now owns 8,130 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 2,627 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Dermira by 5.6% in the 4th quarter. Swiss National Bank now owns 52,600 shares of the biopharmaceutical company’s stock valued at $1,463,000 after acquiring an additional 2,800 shares during the last quarter. 94.67% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2018/03/10/dermira-derm-pt-lowered-to-19-00.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

The Fly

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply